Core A (Administrative Core) will provide all the logistic, scientific, managerial, regulatory and financial support necessary to facilitate and coordinate the studies described in this Consortium. The Administrative Core will ensure that all common and project-specific efforts function optimally and adhere to the timelines described in Program Overview and in the individual projects of this proposal. The Core will organize conference calls every two weeks among Project leaders and other relevant personnel, facilitate regular in-person meetings, maintain regulatory approvals, provide fiscal and logistic oversight, and coordinate meetings with the Scientific Advisory Board and DAIDS Program Officials. The Core will also establish a Scientific Leadership Committee, the primary decision-making body of the Consortium, whose roles include determining allocations of primate resources to individual experiments and consulting in the design of these experiments. The Core will coordinate four annual meetings of this Leadership Committee. The Administrative Core and Scientific Leadership Committee will ensure that all the studies and resources are applied to the primary goals of this proposal. These are: ? to establish the therapeutic utility in HIV-1 infection of a cocktail of antibody or antibody-like entry inhibitors delivered through recombinant adeno-associated virus (AAV) vectors, and ? to identify principles, protocols, and therapeutics directly applicable to human clinical trials. We will support these goals in five Specific Aims: 1. To coordinate communications, interactions, and operations among investigators. Projects, and Cores to facilitate the overall progress and promote the goals of this program project. 2. To coordinate four annual meetings of the Scientific Leadership committee. 3. To ensure and maintain regulatory compliance. 4. To provide detailed financial oversight and management. 5. To coordinate meetings with the Scientific Advisory Board.

Public Health Relevance

The Administrative core is responsible for all fiscal, regulatory, and administrative aspects of this proposal. In addition, it will facilitate communication among Project Leaders, and organize meetings of the Leadership and Scientific Advisory Committees. These activities will promote the broad aim of this Program Project: to establish the therapeutic utility in an ongoing HIV-1 infection of specific cocktails of AAV-delivered antivirals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI100263-01
Application #
8311215
Study Section
Special Emphasis Panel (ZAI1-RB-A (J1))
Project Start
2012-04-01
Project End
2012-11-30
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
1
Fiscal Year
2012
Total Cost
$60,253
Indirect Cost
$15,253
Name
Harvard University
Department
Type
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Martinez-Navio, José M; Fuchs, Sebastian P; Pedreño-López, Sònia et al. (2016) Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. Mol Ther 24:76-86
Gardner, Matthew R; Fellinger, Christoph H; Prasad, Neha R et al. (2016) CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. J Virol 90:7822-32
Rashnonejad, Afrooz; Chermahini, Gholamhossein Amini; Li, Shaoyong et al. (2016) Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene. Mol Biotechnol 58:30-6
Xie, Jun; Burt, Daniel Robert; Gao, Guangping (2015) Adeno-associated virus-mediated microRNA delivery and therapeutics. Semin Liver Dis 35:81-8
Wang, Dan; Mou, Haiwei; Li, Shaoyong et al. (2015) Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. Hum Gene Ther 26:432-42
Fuchs, Sebastian P; Martinez-Navio, José M; Piatak Jr, Michael et al. (2015) AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. PLoS Pathog 11:e1005090
Gardner, Matthew R; Kattenhorn, Lisa M; Kondur, Hema R et al. (2015) AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519:87-91
Ahmed, Seemin S; Gao, Guangping (2015) Making the White Matter Matters: Progress in Understanding Canavan's Disease and Therapeutic Interventions Through Eight Decades. JIMD Rep 19:11-22
Wang, Dan; Gao, Guangping (2014) State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med 18:67-77
Quinlan, Brian D; Joshi, Vinita R; Gardner, Matthew R et al. (2014) A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120. J Virol 88:3353-8

Showing the most recent 10 out of 22 publications